K. Noonan

发表

Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II study

T. Brümmendorf, H. Kantarjian, J. Cortes, 2018, Haematologica.

Long‐term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib

T. Brümmendorf, H. Kantarjian, J. Cortes, 2016, American journal of hematology.

Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations

Ying Cheng, T. Mok, Yi-long Wu, 2020, Drugs.

Management of common adverse events related to first-line dacomitinib use in EGFR mutation-positive non-small-cell lung cancer: a pooled safety analysis.

T. Mok, Yi-long Wu, K. Nakagawa, 2019, Future oncology.

Bosutinib As Third-Line Therapy in Patients (Pts) with Chronic Phase Chronic Myeloid Leukemia (CP CML) Following Failure with Imatinib Plus Dasatinib and/or Nilotinib: 48-Month Update of a Phase 1/2 Study

T. Brümmendorf, H. Kantarjian, J. Cortes, 2014 .

Updated overall survival (OS) from extended follow up in ARCHER 1050: A randomized phase III study comparing dacomitinib with gefitinib as first-line therapy for patients (pts) with EGFR mutations

Ying Cheng, T. Mok, K. Wilner, 2019, Annals of Oncology.

Neoadjuvant talazoparib (TALA) in patients (pts) with germline BRCA1/2 (gBRCA1/2) mutation-positive, early HER2-negative breast cancer (BC): Exploration of tumor BRCA mutational status and zygosity and overall mutational landscape in a phase 2 study.

W. Symmans, M. Danso, A. Abbattista, 2021 .

Neoadjuvant talazoparib in patients with germline BRCA1/2 (gBRCA1/2) mutation-positive, early HER2-negative breast cancer (BC): Results of a phase 2 study.

W. Symmans, J. Chakrabarti, M. Danso, 2021, Journal of Clinical Oncology.

Neoadjuvant Talazoparib in Patients With Germline BRCA1/2 Mutation-Positive, Early-Stage Triple-Negative Breast Cancer: Results of a Phase II Study

W. Symmans, J. Chakrabarti, M. Danso, 2023, The Oncologist.

Neoadjuvant talazoparib in patients with germline BRCA1/2 mutation-positive, early-stage triple-negative breast cancer: exploration of tumor BRCA mutational status

W. Symmans, J. Hopkins, A. Abbattista, 2024, Breast cancer.